Tumor-targeting with stimuli-responsive vesicular nanocarriers : basics to emerging applications / edited by Ankit Jain, Nishit Mody, and Srinath Palakurthi.

Format:

Book

Contributor:

Jain, Ankit, editor.

Mody, Nishit, editor.

Palakurthi, Srinath, editor.

Language:

English

Subjects (All):

Tumors--Immunological aspects.

Tumors.

Physical Description:

1 online resource (741 pages)

Edition:

First edition.

Place of Publication:

London, England : Academic Press, [2025]

Summary:

Tumour-Targeting with Stimuli Responsive Vesicular Nanocarriers: Basics to Emerging Applications not only acquaints scientists and science interns with the fundamental knowledge of the experimental aspects and state-of-the-art technology for vesicular carriers to equip their rational application in tumor targeting, but also provides a holistic.

Contents:

Front Cover

Tumor-Targeting with Stimuli-Responsive Vesicular Nanocarriers

Copyright Page

Contents

List of contributors

1 Anomalous tumor microenvironment: exploitable features for drug delivery

1.1 Introduction

1.2 Tumor microenvironment

1.3 Different types of barriers offered by tumor vasculature

1.4 Angiogenesis and vascular architecture

1.5 Vascularization and localization of nanocarrier in tumors

1.6 Stimuli-sensitive drug delivery systems in cancer

1.6.1 pH-sensitive systems

1.6.2 Temperature-sensitive systems

1.6.3 Enzyme-responsive systems

1.6.4 Redox-responsive systems

1.6.5 Ultrasound-sensitive DDSs

1.6.6 Hypoxia-sensitive DDSs

1.7 Antiangiogenic agent used for normalization of tumor microenvironment

1.8 Conclusion

References

2 Vesicular carriers for stimuli-responsive drug delivery to tumors: design considerations

2.1 Introduction

2.2 Tumor microenvironment

2.2.1 Angiogenesis and tumor vasculature

2.2.2 Metabolic alterations, hypoxia, and inflammatory mediators

2.2.3 Overexpressed enzymes

2.2.4 Overexpressed specific cell surface receptor

2.3 Extrinsic stimuli

2.4 Types of vesicular carriers

2.4.1 Liposomes

2.4.2 Niosomes

2.4.3 Transfersomes

2.4.4 Ethosomes

2.4.5 Sphingosome

2.4.6 Ufasomes

2.4.7 Colloidosomes

2.4.8 Enzymosomes

2.4.9 Bilosomes

2.4.10 Virosomes

2.4.11 Emulsomes

2.5 Stimuli-responsive vesicular carriers

2.5.1 External stimuli-responsive vesicles

2.5.1.1 Ultrasound-responsive nanocarrier

2.5.1.2 Thermal-responsive nanocarriers

2.5.1.3 Magnetic-responsive nanocarriers

2.5.1.4 Light-sensitive nanocarriers

2.5.2 Internal stimuli-responsive nanocarriers

2.5.2.1 Enzyme-responsive nanocarriers

2.5.2.2 pH-responsive nanocarriers

2.5.3 Multimodal-responsive nanocarriers.

2.6 Design considerations for vesicular carriers

2.6.1 Tailoring vesicle size and surface properties

2.6.2 Incorporating targeting ligands for site-specific drug delivery

2.6.2.1 Folic acid-conjugated nanocarriers

2.6.2.2 Carbohydrate-conjugated nanocarriers

2.6.2.3 Peptide-conjugated nanocarriers

2.6.2.4 Aptamer-conjugated nanocarriers

2.6.3 Engineering-responsive elements into vesicular structure

2.7 Characterization of stimuli-responsive vesicular carriers

2.7.1 Vesicular size and surface morphology

2.7.2 Encapsulation efficiency

2.7.3 In vitro evaluation

2.7.4 In vivo evaluation

2.8 Stimuli-responsive vesicular carriers in preclinical and clinical settings

2.9 Regulatory consideration and translation to clinical practice

2.10 Challenges and future perspectives

2.10.1 Emerging trends and future directions

2.11 Conclusion

3 Role of dePEGylation in vesicular carriers-mediated stimuli-responsive drug delivery to tumors

3.1 Introduction

3.2 Stimuli-responsive drug delivery system and targeting mechanism

3.2.1 Types of stimuli-response-based drug delivery systems

3.2.1.1 pH-response-based system

3.2.1.2 Temperature-response-based system

3.2.1.3 Enzyme response-based system

3.2.1.4 Redox response-based system

3.2.1.5 Light-responsive systems

3.2.2 Applications in cancer therapy

3.2.3 Importance in targeted drug delivery to tumors

3.3 PEGylation in drug delivery

3.3.1 Advantages and current challenges of PEGylation

3.3.1.1 Oral administration

3.3.1.2 Safety and immunogenicity

3.3.1.3 Scientific and technological challenges

3.3.1.4 Regulatory consideration

3.4 Tumor-specific stimuli-responsive medication delivery mediated by several forms of dePEGylation in vesicular carriers

3.4.1 Passive dePEGylation.

3.4.1.1 Tumor microenvironment pH

3.4.1.2 Enzymatic cleavage

3.4.2 DePEGylation in response to external stimuli

3.4.2.1 Temperature-sensitive dePEGylation

3.4.2.2 Light-responsive dePEGylation

3.4.2.3 Ultrasound-responsive dePEGylation

3.4.2.4 Magnetic field-responsive dePEGylation

3.4.3 Hybrid strategies

3.4.3.1 Multistimuli-responsive dePEGylation

3.5 Conclusion

4 pH-responsive vesicular carriers as promising tools for tumor targeting

4.1 Introduction

4.2 Low pH characteristics of malignant cells

4.3 Different pH-responsive approaches for tumor targeting

4.4 Recent research studies exploring pH-responsive vesicular carriers for tumor targeting

4.4.1 Liposomes

4.4.2 Micelles

4.4.3 Nanoparticles

4.5 Challenges in the design and use of pH-responsive vesicular drug delivery systems

4.6 Conclusion

5 Enzyme-responsive vesicular carriers as an emerging approach for tumor targeting

5.1 Introduction

5.2 Enzymes responsible for drug release

5.2.1 Proteases

5.2.2 Oxidoreductases

5.2.3 Transferase

5.2.4 Esterase

5.3 Enzyme-responsive polymers for tumor targeting

5.4 Enzyme-responsive vesicular carriers for tumor targeting

5.4.1 Enzyme-responsive liposomes

5.4.2 Enzyme-responsive nanoparticles

5.4.3 Enzyme-responsive micelles

5.4.4 Enzyme-responsive dendrimers

5.5 Challenges and future perspectives

5.6 Conclusion

6 Redox-responsive vesicular carriers for potential tumor-targeting applications

6.1 Introduction

6.2 Tumor microenvironment

6.3 Different types of redox-responsive materials employed for tumor targeting

6.4 Redox-responsive drug delivery systems for tumor targeting

6.4.1 Polymeric and inorganic nanoparticles

6.4.2 Liposomes and lipid-based carriers.

6.4.3 Micelles and polymer-drug conjugates

6.4.4 Dendrimers and hyperbranched polymers

6.4.5 Exosomes and cell-derived vesicles

6.4.6 Hydrogels and nanogels

6.4.7 Nanoemulsions and nanosuspensions

6.5 Clinical translation and challenges

6.6 Conclusion and future perspectives

7 Hypoxia-responsive vesicular carriers for enhanced tumor targeting

7.1 Tumor hypoxia

7.2 Signaling pathways associated with tumor hypoxia

7.3 Hypoxia associated cancer progression

7.3.1 Angiogenesis

7.3.2 Metastasis

7.3.3 Drug resistance

7.4 Current methods of tumor targeting

7.5 Hypoxia-responsive vesicular carriers

7.5.1 Hypoxia-responsive liposomes

7.5.1.1 Composition and design of hypoxia-responsive liposomes

7.5.1.2 Mechanism of action of hypoxia-responsive liposomes

7.5.1.3 Applications of hypoxia-responsive liposomes

7.5.2 Hypoxia-responsive exosomes

7.5.2.1 Applications of hypoxia-responsive exosomes in tumor treatment

7.5.3 Hypoxia-responsive polymersomes

7.5.3.1 Composition of hypoxia-responsive polymersomes

7.5.3.2 Mechanism of action of hypoxia-responsive polymersomes

7.5.3.3 Applications of hypoxia-responsive polymersomes

7.5.4 Hypoxia-responsive niosomes

7.5.4.1 Composition and preparation of hypoxia-responsive niosomes

7.5.4.2 Targeting mechanisms of hypoxia-responsive niosomes

7.5.4.3 Applications of hypoxia-responsive niosomes in cancer treatment

7.6 Conclusion

8 Magnetically responsive and thermo-responsive vesicular carriers for improved drug delivery to tumors

8.1 Introduction

8.2 Stimuli responsive drug delivery systems

8.3 Magnetically responsive drug delivery systems

8.4 Thermo responsive drug delivery systems

8.4.1 Traditional thermo sensitive liposomes

8.4.1.1 Lysolipid thermo sensitive liposomes.

8.4.1.2 Polymer or peptides modified thermo sensitive liposomes

8.4.2 Thermo sensitive niosomes

8.4.3 Thermo sensitive polymersomes

8.5 Dual magnetically and thermo responsive drug delivery system

8.6 Regulatory considerations

8.7 Challenges and future perspectives

8.8 Conclusion

9 Cancer therapy with vesicular drug delivery system and ultrasound assistance

9.1 Introduction

9.2 Cancer therapy via ultrasound-assisted vesicular drug delivery system

9.3 Active-targeting using liposomes

9.3.1 Antibody-modified liposomes (immunoliposomes)

9.3.2 Targeting receptor for epidermal growth factor

9.3.3 Targeting folic receptor

9.3.4 Targeting transferrin receptor

9.3.5 Targeting lactoferrin receptors

9.3.6 Aptamer-modified liposomes

9.3.7 Carbohydrate-modified liposomes

9.3.8 Protein and peptide-modified liposomes

9.4 Mechanism of passive targeting

9.5 Overcoming challenges in passive targeting with vesicular systems

9.5.1 Liposomes in passive targeting

9.5.2 Micelles as passive targeting vehicles

9.5.3 Ultrasound-assisted vesicular systems

9.5.3.1 Stimuli-responsive materials

9.5.3.2 Ultrasound as a trigger

9.5.3.3 Targeted drug delivery

9.5.3.4 Localized drug release

9.5.3.5 Advantages of ultrasound-assisted vesicular systems

9.5.3.6 Challenges and considerations

9.6 Gradient-directed drug delivery to targeted cancerous cells

9.7 Facilitated or equilibrative carrier-mediated gradient diffusion: mechanistic aspect

9.7.1 Where are we today with nanovesicular therapeutics for tumor cells?

9.7.2 Drug transport at bio interfaces: diffusion-based mathematical modeling to understand the transport mechanism

9.8 Conclusion and future perspective

10 Light-triggered vesicular carriers for tumor targeting

10.1 Introduction.

10.2 Benefits of light-sensitive drug delivery.

Notes:

Includes bibliographical references and index.

Description based on publisher supplied metadata and other sources.

Description based on print version record.

ISBN:

9780443291265

0443291268

OCLC:

1515461826